AVR's Principal Activity is the sale, distribution, maintenance and implementation of infusion solutions to major hospitals and health facilities in Australia and New Zealand; The manufacturing, sale and distribution of proprietary ADAPT regenerative tissue products globally; and Continued research and development of regenerative medicine and immunotherapies.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+37.00%|
|vs ASX 200 (1yr)||-0.40%|
|ASX Rank||1204 of 2,564|
|Sector Rank||102 of 177|
Anteris Technologies Ltd (AVR, formerly Admedus Ltd) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings.
Incorporated bioMD Limited was incorporated in June 1999 in Western Australia. Code changed to Allied Healthcare Group Ltd (AHZ) on 30/06/2011
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Stephen (Steve) Denaro||Company Secretary,Non-Executive Director||Oct 2018||
Mr Stephen (Steve) Denaro
Company Secretary,Non-Executive Director
Mr Denaro has more than 30 years of senior level and Board level experience across publicly listed companies; serving as Chief Financial Officer, Company Secretary and Director. He has experience in managing compliance with finance and accounting regulatory requirements. He has managed investment acquisitions and subsequent funding (domestic and international). He also chairs the Risk Management Committee.
|Dr Wenyi Gu||Non-Executive Director||Oct 2018||
Dr Wenyi Gu
Dr Gu works as Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ), where he began his post-doctoral work in 2001. He was supported by the National Health and Medical Research Council (NHMRC) to work at Harvard Medical School, Harvard University as a visiting research fellow. Before he was into nano medicine (focusing on drug delivery and cancer therapy), he worked on RNAi-based gene therapy for several years at Translation Research Institute (TRI). His research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He is a Nominee Non-Executive Director for major shareholder, Star Bright Holding Ltd. He is also a member of Risk Management Committee.
|Mr Wayne Paterson||Managing Director,Chief Executive Officer||Feb 2016||
Mr Wayne Paterson
Managing Director,Chief Executive Officer
Mr Paterson has held senior positions in multi national pharmaceutical companies during the past 25 years. Throughout his career, he has been responsible for building and managing multi-billion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck Kgaa, most recently as President of Europe, Canada and Australia. Prior to this, he was President of Emerging Markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, he served at Roche Pharmaceuticals where he was most recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. He held as a director in Cepheid Inc from April 2015 to November 2016.
|Mr John Seaberg||Non-Executive Director,Non-Executive Chairman||Oct 2014||
Mr John Seaberg
Non-Executive Director,Non-Executive Chairman
Mr Seaberg served as Chairman of the Board of Synovis Inc, a Minneapolis based manufacturer of various medical devices and bio scaffold tissue products from 2008 until its sale to Baxter in 2012. From 2007 until 2014 he was Founder, Chairman and CEO of NeoChord Inc., a venture capital backed company commercializing technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, he served at Guidant Corp (subsequently acquired by Boston Scientific Corp) where he served in various executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, he was co-founder of ACIST Medical and served as its first President and CEO. He is also a member of Member of the Risk Management Committee.
|Matthew McDonnell||Chief Financial Officer||N/A|
|Kiran Bhirangi||Chief Medical Officer||N/A|
|David St Denis||Chief Operating Officer||N/A|
|Martha Engel||General Counsel||N/A|
AVR directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|10/12/20||Wayne Paterson||Expiry||1,000||$3.80||$3,800||Options expired|
|10/12/20||John Seaberg||Expiry||1,000||$3.80||$3,800||Options expired|
|20/03/20||Stephen (Steve) Denaro||Issued||25,000||$3.50||$87,500||Issue of options|
|20/03/20||Wayne Paterson||Issued||350,000||$3.50||$1,225,000||Issue of options|
|20/03/20||John Seaberg||Issued||60,000||$3.50||$210,000||Issue of options|
|18/12/18||John Seaberg||Issued||700,000||$0.08||$56,000||Rights issue|
|18/12/18||Yanheng Wu||Issued||47,178,461||$0.08||$3,774,278||Rights issue|
|18/12/18||Lishan Zhang||Issued||62,897,248||$0.061||$3,836,732||Rights issue|
|18/12/18||Yanheng Wu||Issued||47,178,461||$0.061||$2,877,886||Rights issue|
|18/12/18||Lishan Zhang||Issued||62,897,248||$0.08||$5,031,781||Rights issue|
|08/06/18||Catherine (Kate) Costello||Issued||418,817||$0.124||$51,869||Issue of options|
|08/06/18||Wayne Paterson||Issued||1,435,630||$0.124||$177,798||Issue of options|
The current holdings of AVR directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Stephen (Steve) Denaro||20/03/2020||0||N/A||25,000||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Mercer Street Global Opportunity Fund LLC||20/01/2021||341,545||5.20|
|Star Bright Holding Limited||14/07/2020||730,192||12.35|
|Sio Partners LP||20/01/2021||1,311,079||19.96|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|20-01-21||Mercer Street Global Opportunity Fund LLC||341,545||--||5.20|
|14-07-20||Constellation Immunotherapy Limited||326,951||--||5.53|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|20-01-21||Sio Partners LP||129,809,772||22.20||20.0|
|20-07-20||Constellation Immunotherapy Limited||326,951||5.53||--|
|14-07-20||Star Bright Holding Limited||546,963||21.61||12.3|
|18-06-20||Star Bright Holding Limited||132,176,280||22.62||21.6|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.